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The fidelity of inhibitory neurotransmission is depen-
dent on the accumulation of g-aminobutyric acid
type A receptors (GABAARs) at the appropriate syn-
aptic sites. Synaptic GABAARs are constructed
from a(1-3), b(1-3), and g2 subunits, and neurons
can target these subtypes to specific synapses.
Here, we identify a 15-amino acid inhibitory synapse
targeting motif (ISTM) within the a2 subunit that pro-
motes the association between GABAARs and the
inhibitory scaffold proteins collybistin and gephyrin.
Using mice in which the ISTM has been introduced
into the a1 subunit (Gabra1-2 mice), we show that
the ISTM is critical for axo-axonic synapse formation,
the efficacy of GABAergic neurotransmission, and
seizure sensitivity. The Gabra1-2 mutation rescues
seizure-induced lethality in Gabra2-1 mice, which
lack axo-axonic synapses due to the deletion of the
ISTM from the a2 subunit. Taken together, our data
demonstrate that the ISTM plays a critical role in
promoting inhibitory synapse formation, both in the
axonic and somatodendritic compartments.
INTRODUCTION
Brain function in the mammalian nervous system depends on a
dynamic relationship between excitatory and inhibitory neuro-
transmission (Fritschy, 2008; Selten et al., 2018). Inhibitory inter-
neurons precisely control the firing of excitatory pyramidal
neurons and thus regulate network activity patterns (Roux and
Buzsa´ki, 2015). Interneurons inhibit the activity of pyramidal cells
by releasing the neurotransmitter g-aminobutyric acid (GABA)
onto synapses containing GABA type A receptors (GABAARs).
GABAARs are heteropentameric, ligand-gated ion channels
permeable to chloride. GABAARs can be composed from 19670 Cell Reports 28, 670–681, July 16, 2019 ª 2019 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://different subunits, but synaptic GABAARs are understood to be
primarily assembled from 2 a(1-3), 2 b(1-3), and 1 g2 subunits
(Olsen and Sieghart, 2008; Sigel and Steinmann, 2012). Although
the structure of these subunits is highly conserved, the specific
combination of subunits in a given GABAAR does confer distinct
physiological and pharmacological properties on the receptor
(Goldstein et al., 2002; Rudolph et al., 1999). Subunit types are
also differentially localized within the neuron. For example,
GABAARs containing the a1 subunit tend to be found in dendritic
synapses, while those containing a2 are highly enriched in axo-
axonic synapses at the axon initial segment (AIS) (Klausberger
et al., 2002; Nusser et al. 1996; Nyı´ri et al. 2001), the site of action
potential (AP) initiation (Kole and Stuart, 2012). Recently, it has
been shown that disturbing this subunit distribution in a mouse
model (Gabra2-1) can disrupt inhibitory control of excitation
and lead to seizures and early mortality (Hines et al., 2018).
Clearly, then, pyramidal neurons must precisely control the
allocation of GABAAR subtypes to specific subcellular sites.
The exact mechanisms by which this distribution is attained,
however, remain unclear. Previous work suggests that interac-
tions between the a subunit and intracellular proteins may be a
determinant of GABAAR localization (Mukherjee et al., 2011;
Tretter et al., 2008; Tretter and Moss, 2008). Although the se-
quences of a subunits are largely homologous, there is a signif-
icant area of divergence in the intracellular domain (ICD) that lies
between transmembrane domains 3 and 4 (Olsen and Tobin,
1990). A 15–amino acid sequence within the ICD of a2 has
been shown in vitro to mediate preferential binding to the inhib-
itory synaptic protein collybistin (CB). Replacing this a2-specific
motif with the analogous sequence of a1 causes loss of a2-
containing synapses at the AIS, suggesting that CB may play a
role in the formation of subtype-specific inhibitory synapses via
its interaction with a2 (Hines et al., 2018).
CB is a guanine nucleotide exchange factor that activates the
small GTPase Cdc42, a regulator of the actin cytoskeleton. There
are a number of CB isoforms, but the protein is generally
composed of 3 domains: the pleckstrin homology (PH) phosphoi-
nositide-binding domain, the catalytic RhoGEF (DH) domain, andcreativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. The Gabra1-2 Mutation Alters the
Expression and Surface Stability of Specific
GABAAR Subtypes
(A) Cartoon showing the Gabra1-2 mutation, in
which amino acids 360-375 of the a1 subunit of the
GABAAR are replaced with that of the a2 subunit.
(B) Representative western blots examining
expression of key components of the inhibitory
synapse in total hippocampal lysates. GAPDH
served as a loading control.
(C) Pooled quantification (n = 5 biological and
technical replicates) reveals that the Gabra1-2
mutation leads to a decrease in the total expres-
sion of the a1 subunit, a trending decline in total a2
subunit expression (p = 0.077), and an increase in
total CB expression.
(D) Representative western blots from biotinylated
hippocampal slices examining the surface
expression of the a1 and a2 subunits. Total a1/2
subunit was normalized to GAPDH. Surface a1/2
subunit was normalized to pan-cadherin.
(E) Pooled quantification (n = 5 biological and
technical replicates) shows no change in the
surface:total ratio of the a1 subunit in Gabra1-2
mutants but reveals a significant decrease in the
surface expression of the a2 subunit.
Unpaired t tests with Welch’s correction used for
statistical analysis. (*p < 0.05; **p < 0.01). All data
are expressed as the percentage of WT and error
bars represent mean ± SEM.the N-terminal Src-homology 3 (SH3) domain (Harvey et al., 2004;
Xiang et al., 2006). CB was first identified as a gephyrin-interact-
ing protein (Kins et al., 2000). Gephyrin (GPN) is an integral
component of the inhibitory synapse that is known to binddirectly
to a subunits of GABAARs, forming a submembrane scaffold that
anchors the receptors at the synapse (Mukherjee et al., 2011;
Tretter et al., 2008, 2012). CB binds GPN via the DH domain
and facilitates the aggregation and stabilization of GPN in the
submembrane space (Grosskreutz et al., 2001; Kins et al.,
2000; Tyagarajan et al., 2011). CB-knockout mice display a loss
of both GPN and GABAARs at postsynaptic structures in the
hippocampus (Papadopoulos et al., 2008, 2007), and mutations
in the human CB gene ARHGEF9 are associated with epileptic
diseases (Kalscheuer et al., 2009; Papadopoulos et al., 2015; Shi-
mojima et al., 2011).
CB, therefore, is an attractive candidate for the regulation of
subtype-specific synapse formation, via preferential interactions
with the ICD of a2. However, no study has examined the associ-
ation between CB and the a2 ICD motif in brain tissue or fullyCassessed the effect that this association
has on the trafficking and stabilization
of a1- and a2-containing GABAARs at
synapses. To this end, we developed a
knockin mouse in which the CB binding
motif in the a2 loop is substituted into a1
(the Gabra1-2 mouse). We observed that
this mutation does indeed enhance the
association of the a1 subunit with CB in
brain lysate. The mutation also alters theexpression of a1, causes the enrichment of a1-GABAARs at
the AIS, and increases the size and density of a1-containing syn-
apses in cultured hippocampal cells. In addition, the Gabra1-2
mutation alters both phasic inhibition in the CA1 and baseline
cortical electroencephalographic (EEG) activity, resulting in
resistance to kainate-induced seizures. To demonstrate the
strength of the seizure-resistant phenotype, we crossed
Gabra1-2 mice with Gabra2-1 seizure-prone mice and found
that the double heterozygous animals are spared from the
lethality observed in Gabra2-1 mutants.
RESULTS
The Creation of the Gabra1-2 Mutant Mouse
To probe the interaction between CB and the a2 ICD-binding
motif and determine its importance in synapse formation,
we generated a knockin mouse in which amino acids 360-375
of the a1 ICD were replaced by those of the a2 subunit (Fig-
ure 1A; Figure S1A). Mice were generated using homologousell Reports 28, 670–681, July 16, 2019 671
Figure 2. The Gabra1-2 Mutation Strengthens the Interactions
between the Chimeric a1-2 Subunit and CB
(A) Representative western blots showing co-immunoprecipitation levels of
CB and GPN with the WT and mutant a1 subunit.
(B) Pooled quantification (n = 4 biological and technical replicates) of protein
immunoprecipitation shows a significant reduction in the pull-down of the a1
subunit and significant increases in the pull-down of CB and GPN with the
chimeric a1-2 subunit. Total protein expression data were normalized to
GAPDH, and IP expression data were normalized to total a1 due to the
decrease in total a1 expression in Gabra1-2 mutants.
Unpaired t tests with Welch’s correction were used to analyze data (*p < 0.01;
**p < 0.05; #p < 0.005). Data are expressed as the percentage of WT and error
bars represent mean ± SEM.recombination in ES cells (Genoway), as outlined previously
(Moore et al., 2018; Terunuma et al., 2014; Vien et al., 2015).
To confirm the Gabra1-2 mutation, we amplified the relevant
portion of genomic DNA from wild-type (WT) and homozygous
Gabra1-2 mice and sequenced the resulting PCR product,
confirming the insertion of the a2 amino acid sequence into
a1 (Figure S1B). Mice were genotyped by PCR using primers
that detected the a2 insertion (Figure S1C). Gabra1-2 homozy-
gotes were viable and did not display any overt phenotypes.
Motor behavior, as measured by latency to fall off a rotarod
beam and the total distance traveled in the open field test,
was unaffected (Figure S2). In addition, cresyl violet staining
showed no differences in gross hippocampal anatomy between
WT and mutant animals (Figure S1D).
Changes in GABAAR Trafficking and Surface Stability in
the Gabra1-2 Mouse
Next, we investigated the effect theGabra1-2mutation has on the
expression and trafficking of inhibitory synapse components. To
this end, we immunoblotted total hippocampal lysates for the a1
and a2 subunits, GPN, CB, and synapsin (Figure 1B), as well as
the b3 and g2 subunits (Figure S1E). There were no changes
in the total expression of any of these proteins in heterozygous
Gabra1-2 mice compared with WT (data not shown). In homozy-
gous animals, total levels of synapsin were unchanged, indicating
no widespread changes in synapse formation (Figure 1C). We
found that the total CB was increased in homozygous mutants
compared with controls, while GPN was unchanged (Figure 1C).
We found no changes in either b3 or g2 expression in homozy-
gous animals compared to WT (Figure S1E). Immunoblotting
showed that the total a1 expression decreased in homozygous
Gabra1-2 mutants compared to controls, and total expression672 Cell Reports 28, 670–681, July 16, 2019of a2 also trended toward a decrease (Figure 1C). To examine
these findings in more depth, we performed surface biotinylation
experiments in WT and Gabra1-2 homozygous hippocampal
slices (Figure 1D). To better detect the low levels of surface a2
subunit, these experiments were performed using the previously
described pHlourin-a2 mice (Nakamura et al., 2016)—in which
the a2 subunit is GFP-tagged—crossed with Gabra1-2 animals.
We found that the ratio of surface to total protein for a1 was
unchanged, while that for the a2 subunit was reduced in mutants
compared with controls (Figure 1E), consistent with the decline in
total a2 expression (Figure 1C). Collectively, these results indi-
cate a change in the trafficking of a subunits inGabra1-2mutants:
a2-containing GABAARs are displaced by a1-containing recep-
tors accumulating in the plasma membrane. The data indicating
a depression in total a1 and a2 expression (Figure 1C) was ob-
tained from crude hippocampal lysates, which contain the large
intracellular pool of a subunits. Thus, the reduction in the total
expression of a subunits may reflect a compensatory reduction
in the intracellular pool in response to additional plasma mem-
brane accumulation of a1-GABAARs.
The Gabra1-2 Mutation Enhances the Interaction
between a1 and CB
It has been established that the a2 ICD motif mediates a prefer-
ential interaction with CB over GPN in vitro (Hines et al., 2018). To
confirm this finding in vivo, we performed co-immunoprecipita-
tion (coIP) experiments on forebrain plasma membrane lysates
fromWT and Gabra1-2 mice. Lysates were incubated with mag-
netic beads cross-linked to an N-terminal a1 antibody. Bound
material was eluted from the beads and subjected to SDS-
PAGE, followed by immunoblotting for either a1, CB, or GPN.
a1 immunoblots showed excellent purification of the subunit
from the total lysate and revealed reduced a1 in homozygotes,
in both the input and the immunoprecipitate (IP), consistent
with our earlier results (Figure 1C). Total and immunoprecipitated
CB levels, particularly the high molecular weight isoforms, were
increased in theGabra1-2 IP compared with WT, confirming that
the a2 ICD motif does indeed mediate a preferential association
with CB in vivo (Figure 2). Interestingly, GPN levels were also
increased in the mutant IP compared with WT, indicating an
enhanced interaction between GPN and the mutant a1 subunit
(Figure 2). As it has been previously shown that GPN can bind
both a subunit ICDs and CB (Grosskreutz et al., 2001; Mukherjee
et al., 2011; Tyagarajan et al., 2011), these data suggest that,
via binding at the a2 ICD motif, GABAARs, CB, and GPN form
a synergistic tripartite complex in which strengthening the inter-
action between two partners enhances the stability of the entire
complex.
The Gabra1-2 Mutation Is Sufficient to Target a1-
Containing GABAARs to the AIS
Our previous work has demonstrated that the a2 ICD motif is
necessary for the accumulation of GABAARs at the AIS (Hines
et al., 2018). To determine if thismotif is sufficient for the formation
of these precisely localized synapses, we performed immu-
nocytochemistry (ICC) on WT and Gabra1-2 homozygous DIV21
hippocampal neurons. ICCwas selected to allow for superior res-
olution of subcellular compartments, including the AIS. Neurons
Figure 3. The Gabra1-2 Mutation Induces
the Accumulation of Chimeric a1-2 Subunits
at Synapses in the Soma, Dendrites, and AIS
(A and C) Immunocytochemical (ICC) analysis of
the subcellular distribution of the a1 and a2 sub-
units of theGABAAR inWT and homozygous DIV21
hippocampal neurons. Neurons were stained with
antibodies against AIS markers (green) and either
a1 (A, red) or a2 (C, red). Insets showmagnification
of representative AIS segments. White arrows
indicate synaptic clusters of mutant a1-2 on the
AIS.
(B) Pooled quantification (n = 3 biological and
technical replicates, N = 30 cells/genotype) of
puncta density, defined as the number of puncta
per 10 mm of neurite or soma, reveals that in
Gabra1-2 mutants, a1 puncta are significantly
denser and larger compared with WT in all
neuronal compartments examined.
(D) Pooled quantification (n = 3 biological and
technical replicates, N = 30 cells/genotype) dem-
onstrates no change in the distribution of the a2
subunit in Gabra1-2 mutants compared to WT.
Scale bar, 10 mm (low mag); scale bar, 5 mm (AIS
inset).
Unpaired t tests were used to analyze data (*p <
0.0001). Error bars represent mean ± SEM.were co-labeled with antibodies against AIS markers (pan-Na+
and ankyrin G, together) and either the GABAAR a1 or a2 subunit.
Imaging revealed a striking phenotype: chimeric a1-containing
GABAARs formed significantly denser and larger puncta on
Gabra1-2 AIS segments, compared with WT AIS segments (Fig-
ures 3A–3B). In addition, the number and size of synapsespositive
for the a1 subunit was far larger in the somatodendritic compart-
ments of mutant neurons (Figures 3A–3B). Experiments exam-
ining the localization of a2-containing GABAARs showed neither
changes in the levels of a2 at the mutant AIS nor alterations in
the density or size of a2 positive synaptic puncta (Figures 3C–
3D). These results indicate that the a2 360-375 motif does not
simply allow GABAARs to access and remain at the AIS, but it
also stabilizes receptors at synapses versus the extrasynaptic
space in the soma and dendrites, providing a mechanism for
the previously observed greater synaptic clustering of the a2
subunit (Tretter et al., 2008). This interpretation is strengthened
by data from a co-localization analysis performed on whole neu-
rons showing that the co-localization of a1 puncta and the vesic-
ular GABA transporter (VGAT, presynaptic marker), as measuredCby the Pearson’s correlation coefficient,
was significantly increased in Gabra1-2
neurons (Figures S3A–S3B). In addition,
the co-localization of a1 puncta and GPN
puncta was significantly increased in
mutant neurons (Figures S3C–S3D). In
contrast, the Gabra1-2 mutation does not
affect the co-localization of a2 and VGAT
(Figures S4A–S4B).
To ensure that there were no gross
changes in inhibitory synapse formation,neurons were co-labeled for AIS markers, GPN, and VGAT.
Co-localization between GPN and VGAT puncta was unchanged
by the Gabra1-2 mutation (Figures S4C–S4D). Further analysis
revealed a significant increase in the density and size of VGAT
puncta specifically in the soma and dendrites of Gabra1-2 neu-
rons, with VGAT distribution at the AIS unchanged (Figure S5).
Analysis of GPN puncta showed the opposing effect: GPN
puncta at the AIS were significantly smaller and more numerous
in Gabra1-2 neurons when compared with WT controls, with no
changes in the soma and dendrites (Figure S6). These results
indicate that, in response to the increase in a1 positive synapses
on pyramidal neurons, only inhibitory interneurons contacting
the soma and dendrites create more presynaptic terminals.
The change in AIS GPN from the one or two large cartridges
seen in WT (Figure S6A) neurons to small, numerous puncta in
mutants suggests that increased stabilization of the chimeric
a1-GABAARs at the AIS requires a reconfiguration of the post-
synaptic structure. To investigate this phenomenon further, neu-
rons were labeled with antibodies against AIS markers and CB.
Unfortunately, CB staining produced a diffuse stain throughoutell Reports 28, 670–681, July 16, 2019 673
Figure 4. Miniature Inhibitory Postsynaptic Currents (mIPSC) Kinetics Are Altered in the Gabra1-2 Hippocampus
(A) Representative mIPSC recordings from pyramidal neurons in the CA1 of WT andGabra1-2 hippocampal slices, with superimposed spikes (right) representing
the average WT (black) and Gabra1-2 traces (red).
(B and C) Quantification of mIPSC kinetics (n = 6mice/genotype in 3 cohorts) shows no effect of themutation onmIPSC frequency (B), but (C) reveals a significant
decrease in the mIPSC decay time.
(D) Analysis of tonic inhibition in the CA1 (n = 8mice/genotype in 4 cohorts) showed no difference betweenWT and homozygous animals. In-depth analysis of CA1
pyramidal neuron mIPSC amplitudes fromWT and Gabra1-2 hippocampal slices (n = 6 mice/genotype in 3 cohorts) revealed a shift toward more high amplitude
events in Gabra1-2 mutants.
(legend continued on next page)
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Figure 5. The Gabra1-2 Mutation Produces
Baseline Abnormalities in Cortical Electro-
encephalographic (EEG) Recordings
(A) Spectrograms of representative WT and
Gabra1-2 (n = 9 mice/genotype in 3 cohorts) EEG
recordings without pharmacological manipulation.
(B) Power spectral density (PSD) plot of 10 minutes
of awake baseline EEG activity.
(C) Pooled quantification of the relative power of
binned frequency bands revealed a significant in-
crease in the relative power of the a band (8–13 Hz)
in Gabra1-2 mutants compared with WT littermate
controls. Datawere analyzed using unpaired t tests
(*p < 0.05). Error bars represent mean ± SEM.the neuron, impeding analysis of any changes in the subcellular
distribution of CB (Figure S7).
Faster Mini Inhibitory Postsynaptic Current (mIPSC)
Decay Times and a Shift in mIPSC Amplitude
Distribution in Gabra1-2 Neurons
Our biochemical and immunostaining experiments revealed
changes in the expression and clustering of mutant a1-contain-
ing GABAARs, creating larger and denser inhibitory synapses. To
assess any effects these alterations could have on inhibitory syn-
aptic signaling, we examined the kinetics of mIPSCs in CA1
pyramidal neurons (Figure 4A). The frequency of mIPSCs was
unaffected by the Gabra1-2 mutation (Figure 4B). mIPSC decay
times were significantly decreased in mutant neurons compared
with WTs (Figure 4C). Examination of tonic inhibition in the CA1
showed no changes between WT and homozygous mice (Fig-
ure 4D). While the average mIPSC amplitude was unchanged
(data not shown), further analysis showed that the Gabra1-2
mutation increased the proportion of high amplitude events (Fig-
ures 4E–4F). Fitting the data to Gaussian curves showed that the
mIPSC amplitude distribution in WTmice was best described by
the sum of 3 Gaussian components (Figure 4G); in Gabra1-2
mice, however, the mIPSC amplitude distribution was best
described as the sum of 4 Gaussian components, with the first
three similar in amplitude to the WT components and the fourth
consisting of a high amplitude component exclusive toGabra1-2
mutants (Figure 4H). These data demonstrate that enhancing the
size and density of inhibitory synapses promotes inhibitory
neurotransmission.(E and F) The relative (E) and cumulative (F) frequency of mIPSC events of different amplitudes.
(G and H) Fitting the data to Gaussian curves and creating mIPSC histograms for WT (G) and Gabra1-2
amplitude (Peak 4, blue, mean = 80.7 pA) curve in mutants that does not exist in WT. This result indicates
exclusively in Gabra1-2 hippocampal slices.
Mann-Whitney tests were used to analyze mIPSC kinetics and tonic current data (#p < 0.05) and error bars re
and (H), data are expressed as mean ± SEM amplitudes (pA) for each of the Gaussian components used to
CAlterations in Baseline EEG Activity
in Gabra1-2 Mice
Gabra1-2 mice experience changes in the
distribution of subtype-specific GABAARs
and presynaptic inputs, as well as
enhanced inhibitory neurotransmission.
Given that inhibitory control of pyramidalneurons is known to play an important role in the generation of
cortical oscillations measured by EEG (Buzsa´ki and Chrobak,
1995; Mann et al., 2005; Roux and Buzsa´ki, 2015), we assessed
baseline cortical EEG activity in WT and Gabra1-2 mice. Mice
were recorded for at least 1 hour of wakefulness one week
following EEG/electromyogram (EMG) implantation. Representa-
tive spectrograms and fast-Fourier transformation of 10 minutes
of this awake EEG activity showed changes in specific frequency
bands between WT and Gabra1-2 littermate controls (Figures
5A–5B). To examine these changes in more depth, we parsed
the EEG activity into the following frequency bands: d (1–4 Hz),
q (4–8 Hz), a (8–13 Hz), b (13–30 Hz), low g (30–50 Hz), and
high g (50–100 Hz). Comparison of the relative power of each
of these bands between WT and Gabra1-2 animals revealed a
significant elevation in the a range in mutants compared with
WT (Figure 5C).
Resistance to Kainate-Induced Seizures in Gabra1-2
Mice
Electrophysiological experiments show that inhibitory neuro-
transmission is changed inGabra1-2 mice. To determine if these
physiological changes affect seizure susceptibility, known to be
at least partially dependent on inhibitory control of excitation
(Fritschy, 2008), we employed the kainate model. Kainate (KA,
20 mg/kg, i.p.) was administered to WT and homozygous adult
male littermates that were previously implanted with cortical
EEG and EMG monitors. Using the EEG and EMG data to deter-
mine the onset of epileptic activity and status epilepticus (SE)
(Figures 6A–C), we found that homozygous animals experienced(H) demonstrates the existence of a fourth, higher
that a population of high amplitude mIPSCs occurs
present mean ± SEM for these experiments. For (G)
obtain optimal fits to the data.
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Figure 6. The Gabra1-2 Mutation Confers Resilience to Kainate-Induced Seizures
(A) Representative EEG recordings and spectrograms from WT and Gabra1-2 mice injected with 20 mg/kg of kainate (n = 9 mice/genotype in 3 cohorts). The
beginning of the trace represents 30 s after the time of injection.
(B and C) Arrows indicate traces expanded in (B) for WT (black) and (C) for homozygote (red). For both (B) and (C), trace 1 (top) represents baseline activity shortly
after kainate injection, and trace 2 (bottom) represents the first tonic-clonic seizure.
(legend continued on next page)
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their first tonic-clonic seizure later than WT littermate controls
(Figure 6D). In addition, the latency to entering SE was longer
in homozygous mice (Figure 6E). Mutant animals also exhibited
resilience to SE-induced mortality: no homozygous animals
died in the two hours following KA injection, while about 40%
of WTs died during SE (Figure 6F). To explore the nature of
epileptic activity in Gabra1-2 animals further, we performed
fast-Fourier transformation on EEG recordings of SE and parsed
the recordings into the specific frequency bands outlined
above. This analysis revealed that Gabra1-2 mice experienced
a specific reduction in the relative power of the high g band
(50–100 Hz) during SE (Figures 6G–6H). Collectively, these
data show that themolecular and physiological changes induced
by the Gabra1-2 mutation provide resilience to KA-induced sei-
zures by blunting high g power.
The Gabra1-2 Mutation Rescues Early Mortality in
Gabra2-1 Mice
Gabra2-1 mice possess a chimeric a2 subunit in which residues
360–375 from the a1 subunit have been knocked in to replace
the normal a2 ICD motif. This mutation leads to a loss of inhibi-
tory synapses at the AIS. Both heterozygous and homozygous
Gabra2-1 pups display early mortality, with death peaking at
postnatal day 20 (PND20) due to spontaneous seizure activity
(Hines et al., 2018). To determine if the Gabra1-2 mutation
rescues the Gabra2-1 mortality phenotype, homozygous Ga-
bra1-2 mice were crossed with homozygous Gabra2-1 mice.
The resulting offspring were genotyped by PCR with primers
that detected both the a1 and a2 insertions and were confirmed
to be heterozygous for bothmutations (Figure 7A).Gabra2-1 het-
erozygous pups and Gabra1-2/Gabra2-1 double heterozygous
pups were monitored each day after birth until PND40. Of the
double heterozygous pups, 100% survived to PND40 compared
with only 61%of theGabra2-1 heterozygous animals (Figure 7B),
demonstrating that the Gabra1-2 mutation and subsequent
phenotype can rescue early mortality in Gabra2-1 animals, likely
by promoting the synaptic localization of chimeric a1-GABAARs.
DISCUSSION
We have provided evidence that the a2 360-375 ICDmotif medi-
ates a preferential interaction with CB in vivo and that the pres-
ence of this motif in a given GABAAR is sufficient to stabilize
that receptor at the AIS. In addition, the a2 motif may constitute
an ‘‘inhibitory synaptic targeting’’ signal, generally enhancing the
anchoring of GABAARs in the synaptic space, as the Gabra1-2
mutation caused the accumulation of chimeric a1-GABAARs at(D) The onset of the first tonic-clonic seizure event is delayed in Gabra1-2 mutan
percentage of WT.
(E) The onset of status epilepticus (SE) was delayed in Gabra1-2 mutants. Data a
(F) Kainate-inducedmortality was reduced inGabra1-2 animals comparedwithWT
mice at the corresponding time after kainate injection.
(G) PSD plot of the first hour of EEG activity after kainate injection.
(H) Pooled quantification of the relative power of binned frequency bands during
(50–100 Hz) to total EEG power during SE in Gabra1-2 mutants.
Data from (D), (E), and (H) were analyzed with unpaired t tests (*p < 0.05). Data
represent mean ± SEM.somatodendritic synapses, altering inhibitory neurotransmission
and baseline network oscillations. These changeswere sufficient
to ameliorate the severity of kainate-induced seizure activity. The
Gabra1-2 mutation was also sufficient to rescue the lethal
seizure phenotype previously described inGabra2-1mice (Hines
et al., 2018).
Unexpectedly, given that recent in vitro data showed a rela-
tively low affinity between GPN and the a2 ICD motif (Hines
et al., 2018), the Gabra1-2 mutation also led to an enhanced
in vivo interaction between the chimeric a1 subunit and GPN.
Previous work in Y2H systems has suggested that GPN, CB,
and the a2 subunit form a trimeric complex; interactions be-
tween GPN/a2 and CB/a2 were potentiated in the presence of
CB and GPN, respectively (Saiepour et al., 2010). In addition,
a2-GABAARs are more clustered at synapses than those con-
taining a1, a phenomenon at least partially dependent on the
presence of GPN (Tretter et al., 2008). Our results support the
notion of a ‘‘tripartite complex’’ composed of GPN, CB, and an
a2 subunit, in which strengthening the interaction between two
of the complex’s partners stabilizes the entire trimer. GABAARs
are known to be initially inserted into the plasma membrane ex-
trasynaptically (Bogdanov et al., 2006; Thomas et al., 2005); they
then laterally diffuse via Brownian motion until they contact scaf-
folding proteins in the synaptic space. These scaffolding pro-
teins, including GPN (Jacob et al., 2005), contact the receptors,
slowing their diffusion rate and immobilizing receptors at the syn-
apse (Choquet and Triller, 2013; Renner et al., 2008; Triller and
Choquet, 2005, 2008). Previous work has shown that the g2 sub-
unit is necessary for the synaptic anchoring process (Alldred
et al., 2005); however, the g2 subunit is promiscuous and is an
unlikely candidate for GABAAR subtype-specific synaptic target-
ing. We demonstrate that a GPN-CB complex could act as a
subtype-selective structural anchor at the synapse, specifically
interacting with only those a subunits containing the a2 ICD
motif, creating a super-stable trimer that anchors the GABAAR
component at the synapse. The increased synaptic clustering
of mutant a1-GABAARs seen in the Gabra1-2 mouse is likely
due to increased recruitment of these receptors from the extra-
synaptic space to the synapse via the a2 motif-CB-GPN interac-
tion. In the AIS, where a2 is particularly enriched, the presence of
the trimeric complex would be especially important for the stabi-
lization of a2-GABAARs. a1-GABAARsmay be able to access the
AIS but will not stabilize as effectively at axo-axonic synapses
due to a1’s weaker interaction with CB. Other proteins that are
essential in AIS structure—including Ankyrin G and bIV-spectrin
(Susuki and Rasband, 2008)—may also interact with the trimeric
complex and/or the a2 ICD motif. Future research shouldts compared with WT littermate controls. The time of onset is displayed as a
re displayed as a percentage of WT littermate control.
littermates. The survival plot shows the percentage of death ofWT andmutant
5 minutes of SE revealed a specific decrease in the contribution of high g band
from (F) was analyzed with a log-rank (Mantel-Cox) test (*p < 0.05).Error bars
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Figure 7. The Gabra1-2 Mutation Rescues the Gabra2-1 Lethal
Seizure Phenotype
(A) Genotyping for a Gabra1-2 homozygous (+/+) positive control, a Gabra2-1
homozygous (+/+) positive control, and two Gabra1-2/Gabra2-1 double het-
erozygous (+/) animals. Primers to detect the a1-2 and the a2-1 mutation
were used on both double heterozygotes.
(B) The Gabra1-2 mutation rescues the lethal seizure phenotype that leads
to early mortality in Gabra2-1 heterozygotes. Data are shown as a percentage
of Gabra2-1 and double heterozygous animals alive at a given time after birth
(n = 20 mice/genotype).investigate potential interactions between the a2 subunit and
these AIS components and test the necessity of such interac-
tions to the presence of GABAARs at the AIS.
In the chimeric Gabra1-2 mouse, a1-GABAARs containing the
a2 ICD motif acquire an ‘‘a2-like’’ pattern of distribution, with
greater synaptic clustering resulting in the proliferation of inhibi-
tory synapses. Affected neurons undergo some compensation in
response to these changes: reducing total levels of a1 subunit
expression, increasing CB expression, and displacing surface
a2-GABAARs. Still, our data demonstrate that the Gabra1-2
mutation enhances inhibitory neurotransmission. Larger propor-
tions of high-amplitude mIPSCs are a result of the significant678 Cell Reports 28, 670–681, July 16, 2019increase in large, stable inhibitory synapses in Gabra1-2 neu-
rons, while changes in decay kinetics likely reflect an alteration
in the type of GABAARs on the surface. Different a subunit com-
positions have been previously shown to affect mIPSC decay
time (Goldstein et al., 2002); an increase in the proportion of
a1-GABAARs at the synapse could shift the type of decay seen
in mIPSC recordings.
Interestingly, our data demonstrate that the alterations in inhib-
itory neurotransmission caused by the Gabra1-2 mutation per-
turb network activity and result in abnormal EEG activity at
baseline. Specifically,Gabra1-2mice show an increase in the po-
wer of the a band. Inhibitory interneurons are thought to shape
neuronal oscillations (Klausberger and Somogyi, 2008), including
the a band (Lozano-Soldevilla, et al., 2014), and it is likely that the
constitutive Gabra1-2 mutation also affects interneurons them-
selves, as shown by the observed increase in VGAT positive pre-
synaptic contacts onto mutant pyramidal neurons. TheGabra1-2
mutation may also affect the interplay between interneurons and
pyramidal neurons within neuronal networks. Either of these two
putative effects could cause changes in network synchrony.
Future research into the specific effect of the Gabra1-2 mutation
on interneurons, particularly experiments examining changes
in the types of interneurons contacting pyramidal cells, would
elucidate the mechanisms at play. Furthermore, in both humans
and mice the a frequency band is associated with behavioral in-
hibition, a process that underlies a variety of cognitive tasks,
including attention and working memory (Knyazev, 2007). In
addition, benzodiazepine sedation induces a decrease in a
band power (Hotz et al., 2000). Future research should examine
the possibility that Gabra1-2 mice may be resistant to the seda-
tive effects of these GABAergic pharmacological agents and
may also perform better at tasks measuring behavioral inhibition,
such as the Go/No-Go task (Gubner et al., 2010).
While the mechanisms of ictogenesis remain unclear, it is
generally accepted that inhibitory control of excitation is a
contributing factor (Fritschy, 2008). In addition, AIS dysfunction
and mutations in the human CB gene ARHGEF9 are both linked
to epileptic disorders in humans (Buffington and Rasband, 2011;
de Groot et al., 2017; Kalscheuer et al., 2009; Shimojima et al.,
2011; Wimmer et al., 2010). The Gabra1-2 mutation enhances
inhibitory neurotransmission, resulting in a reduction in the
susceptibility of Gabra1-2 mice to kainate-induced seizures.
Intriguingly, neuronal activity during SE seems to be altered:
the Gabra1-2 mutation blunts the increase in g band power
commonly seen during SE (Sharma et al., 2018). Inhibitory inter-
neurons are thought to shape neuronal oscillations, including
the g band (Mann et al., 2005; Wang et al., 2016), via synchroni-
zation of large pyramidal cell networks (Klausberger and Somo-
gyi, 2008) and have been found to undergo morphological
and functional changes in animal models of epilepsy (Smith,
2014). The Gabra1-2 mutation may prevent or compensate
for KA-induced aberrant interneuron activity, thus mitigating
pathological neuronal synchronization, ameliorating SE severity,
and promoting survival. Interestingly, other genetic manipula-
tions that affect GABAergic transmission have been shown
to blunt g power and SE severity in the same way as the
Gabra1-2 mutation (Moore et al., 2018), suggesting a possible
common pathway to reducing SE severity and mortality.
In the previously described Gabra2-1 mouse model, the ICD
motif of the a2 subunit is replaced with that of a1. Consistent
with the proposed importance of the a2 ICD motif in the sta-
bilization of GABAARs at the AIS and elsewhere, Gabra2-1 an-
imals lose both the majority of inhibitory synapses at the AIS
and inhibitory synapses that oppose parvalbumin positive in-
puts in the somatodendritic compartments. Gabra2-1 mice,
both heterozygous and homozygous, experience sponta-
neous seizures in the postnatal period, often leading to early
mortality around PND20 (Hines et al., 2018). Given that
the Gabra1-2 mutation seems to lead to the opposite effects
of the Gabra2-1 mutation, it is perhaps unsurprising that
crossing these two strains results in a rescue of the early mor-
tality phenotype of Gabra2-1 animals. The restoration of inhib-
itory synapses at the AIS and the increase in size and density
of a1-containing synapses due to the Gabra1-2 mutation likely
compensates for the loss of a2-mediated inhibitory neuro-
transmission in Gabra2-1 mice. Importantly, the Gabra2-1 mu-
tation reproduces the effects of many epileptogenic ARHGEF9
mutations in humans (Hines et al., 2018); the rescue of
Gabra2-1 by Gabra1-2 suggests that manipulating the distri-
bution of a1-GABAARs or targeting the CB-GPN-a2 complex
could represent new avenues for research into therapies for
ARHGEF9-associated disorders.
Taken together, we report evidence of a preferential interac-
tion in vivo between CB and the a2 ICD motif and show that
this interaction is sufficient to stabilize GABAARs at the AIS.
Our data support the theory of a trimeric CB-GPN-a2 subunit
complex at inhibitory synapse and present a possible explana-
tion for the higher synaptic clustering of a2-GABAARs over
a1-GABAARs. These insights improve our understanding of the
subtype-specific inhibitory synaptogenesis that is so important
for normal brain function. Finally, Gabra1-2 mice are resilient to
kainate-induced seizures and rescue the ictogenic effects of
the Gabra2-1 mutation, revealing a new avenue of investigation
into treatments of epileptic disorders.STAR+METHODS
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Ankyrin-G (staining) scaffold protein monoclonal
mouse
UC Davis/NIH NeuroMab Facility Cat# 73-146; RRID:AB_10697718
Anti-GABAAR b3 mouse monoclonal UC Davis/NIH NeuroMab Facility Cat# 75-149; RRID: AB_2109585
Anti-Cadherin, pan Rabbit polyclonal Cell Signaling Cat# 4068; RRID:AB_2158565
Anti-Collybistin rabbit polyclonal Synaptic Systems Cat# 261 003; RRID:AB_2619977
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Anti-GABAAR a2 N-terminal rabbit polyclonal Synaptic Systems Cat# 224 103; RRID:AB_2108839
GABAAR a2 C-terminal rabbit polyclonal Phosphosolutions No longer available
Anti-GABAAR g2L mouse monoclonal UC Davis/NIH NeuroMab Facility Cat #75-442; RRID: AB_2617122
GAPDH rabbit polyclonal Santa Cruz No longer available
Anti-Gephyrin 3B11 mouse monoclonal Synaptic Systems Cat# 147 111; RRID:AB_887719
Anti-Gephyrin mAb7a mouse monoclonal Synaptic Systems Cat# 147 011; RRID:AB_887717
Anti-Gephyrin RbmAb7a rabbit monoclonal Synaptic Systems Cat# 147 008; RRID:AB_2619834
Anti-GFP Antibody, Unconjugated chicken
polyclonal
Cell Signaling Cat# 2555; RRID:AB_10692764
Anti-Sodium Channel, Pan antibody mouse
monoclonal
Sigma Aldrich Cat# S8809; RRID:AB_477552
Anti-Synapsin 1 antibody mouse monoclonal Synaptic Systems Cat# 106 011; RRID:AB_2619772
Anti-VGAT antibody guinea pig polyclonal Synaptic Systems 131 004; RRID:AB_887873
Donkey anti-mouse peroxidase conjugated Jackson ImmunoResearch Cat# 715-036-151; RRID:AB_2340774
Donkey anti-rabbit peroxidase conjugated Jackson ImmunoResearch Cat# 711-036-152; RRID:AB_2340590
Goat anti-guinea pig Alexa Fluor 647 ThermoFisher Scientific Cat# A-21450; RRID:AB_2735091
Goat anti-mouse Alexa Fluor 488 ThermoFisher Scientific Cat# A28175; RRID:AB_2536161
Goat anti-rabbit Alexa Fluor 568 ThermoFisher Scientific Cat# A-11011; RRID:AB_143157
Chemicals, Peptides, and Recombinant Proteins
1 M CaCl2 Sigma Aldrich Cat#: 21114
1 M KCl Sigma Aldrich Cat#: 60121
1 M MgCl2 Sigma Aldrich Cat#: 63020
10x Phosphate Buffered Saline (PBS) ThermoFisher Scientific Cat#: BP399-4
32% PFA stock solution Electron Miscroscopy Sciences Cat#: 15714S
Acetic acid, glacial ThermoFisher Scientific Cat#: A38-212
Bovine Serum Albumin (BSA) Sigma Aldrich Cat#: A7906
Cresyl violet acetate Sigma Aldrich Cat#: C-5042
CsCl Sigma Aldrich Cat#: C4036
CsOH Sigma Aldrich Cat#: C8518
D-Glucose Sigma Aldrich Cat#: G8270
Dehydrated milk Amazon https://amazon.com/Emergency-Essentials-
Instant-Nonfat-Milk/dp/B003SQ98EC
Ethanol, 200 proof VWR Cat#: 89125-172
Ethylene glycol-bis(2-aminoethylether)-
N,N,N0,N0-tetraacetic acid (EGTA)
Sigma Aldrich Cat#: E3889
Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich Cat#: E9884
EZ-Link Sulfo-NHS-SS-Biotin ThermoFisher Scientific Cat#: 21328T
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Fisher Healthcare Tissue-Plus O.C.T. Compound ThermoFisher Scientific Cat#: 23-730-571
GABA Sigma Aldrich Cat#: A2129
GIBCO B27 (50x) ThermoFisher Scientific Cat#: 17504044
GIBCO GlutaMAX Supplement ThermoFisher Scientific Cat#: 35050061
GIBCO Penicillin/streptomycin (10,000 U/mL) ThermoFisher Scientific Cat#: 15140122
GIBCO Trypsin (2.5%), no phenol red ThermoFisher Scientific Cat#: 15090046
Glycine VWR Cat#: 0167
Invitrogen 1 M HEPES buffer solution ThermoFisher Scientific Cat #: 15630080
Invitrogen HBSS, 10X, no phenol red,
no calcium, no magnesium
ThermoFisher Scientific Cat#: 14185-052
Invitrogen MES SDS Running Buffer 20x Thermofisher Scientific Cat#: NP0002
Invitrogen NuPAGE LDS Sample Buffer 4x ThermoFisher Scientific Cat#: NP0007
Invitrogen ProLong Gold Antifade Mounting
Reagent
Thermo Fisher Scientific Cat#: P36930
Invitrogen Protein A Dynabeads ThermoFisher Scientific Cat#: 10001D
Isofluorane Piramal Healthcare Cat#: NDC 66794-013-25
Kainic Acid (Kainate) Sigma Aldrich Cat#: K0250
Kynurenic Acid Sigma Aldrich Cat#: K337
L-glutamine Sigma Aldrich Cat#: G8540
Laminin Sigma Aldrich Cat#: L2020
Mannitol Sigma Aldrich Cat#: M4125
Meglumine (NMDG) Sigma Aldrich Cat#: M9179
Methanol Sigma Aldrich Cat#: 179337
Mg-ATP Sigma Aldrich Cat#: A9187
MgSO4 Sigma Aldrich Cat#: M3409
Na-ascorbate Sigma Aldrich Cat#: A7631
Na-GTP Sigma Aldrich Cat#: G8877
NaCl Sigma Aldrich Cat#: S7653
NaF Sigma Aldrich Cat#: S7920
NaH2PO4 Sigma Aldrich Cat#: S9638
NaHCO3 Sigma Aldrich Cat#: S6297
Neurobasal-A Medium, serum-free ThermoFisher Scientific Cat#: 10888022
Normal Goat Serum (NGS) Abcam Cat#: ab7481
Pierce Streptavidin Agarose beads ThermoFisher Scientific Cat#: 20347
Pierce BCA Protein Assay Kit ThermoFisher Scientific Cat#: 23225
Pierce ECL Western Blotting Substrate ThermoFisher Scientific Cat#: 32106
Poly-L-Lysine hydrobromide Sigma Aldrich Cat#: P1274
Roche cOmplete, Mini Protease Inhibitor
Cocktail
Sigma Aldrich Cat#: 11836153001
Roche PhosSTOP Sigma Aldrich Cat#: 4906845001
Sodium orthovanadate Sigma Aldrich Cat#: 450243
Sodium pyruvate Sigma Aldrich Cat#: P3662
Sucrose VWR Cat#: 0335
Tetrodotoxin (TTX) Tocris Cat#: 1069
Thiourea Sigma Aldrich Cat#: 8658
Tris VWR Cat#: 0497
Triton X-100 Sigma Aldrich Cat#: T8787
(Continued on next page)
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Tween-20 Sigma Aldrich Cat#: P2287
b-mercaptoethanol Sigma Aldrich Cat#: 63689
Experimental Models: Organisms/Strains
Mouse: Gabra1-2(/) Mouse: Gabra1-2(+/)
Mouse: Gabra1-2(+/+)
This paper N/A
Mouse: pHlourin-a2(+/+) Mouse: pHlourin-
a2(+/+)/Gabra1-2(+/+)
Nakamura et al., 2016 N/A
Mouse: Gabra2-1(+/)/Gabra1-2(+/) Hines et al., 2018; This paper N/A
Oligonucleotides
Gabra1-2 Genotyping Forward Primer: 50-GGGTC
GACAACTATTTCACCAAGAGAGG-30
Integrated DNA Technologies N/A
Gabra1-2 Genotyping Reverse Primer: 50-GGGC
GGCCGCTTATCGGTCGATTTTGCTGACGC-30
Integrated DNA Technologies N/A
Gabra1-2 Sequencing Primer 1: 50-TGCCAGGGA
GTCTAACCGT-30
Integrated DNA Technologies N/A
Gabra1-2 Sequencing Primer 2: 50-CAAATAGCA
GCGGAAAGGCT-30
Integrated DNA Technologies N/A
Gabra1-2 Sequencing Primer 3: 50-CTGCCAGG
GAGTCTAACCGT-30
Integrated DNA Technologies N/A
Gabra1-2 Sequencing Primer 4: 50-GACAGTCG
GTCGATTTTGCTG-30
Integrated DNA Technologies N/A
Software and Algorithms
GraphPad Prism, v.7.01 GraphPad Software RRID:SCR_002798 https://www.graphpad.com
Image Lab, v.5.0 Bio-Rad RRID:SCR_014210 http://www.bio-rad.com
ImageJ v.2.0.0 Fiji RRID:SCR_002285 https://imagej.net
LabChart v.7.3.8 AD Instruments RRID:SCR_001620 https://www.adinstruments.
com/products/labchart
MetaMorph, v.7.8.0.0 Molecular Devices RRID:SCR_002368 https://www.
moleculardevices.com
Mini-Analysis Software v.5.6.4 Synaptosoft http://www.synaptosoft.com/MiniAnalysis/
MotorMonitor Kinder Scientific http://kinderscientific.com/products/open_field
NIS-Elements, v.4.20 Nikon RRID:SCR_014329 https://www.microscope.
healthcare.nikon.com/products/software
pClamp v.10.3 Moleclular Devices RRID:SCR_011323 https://www.
moleculardevices.com
Sirenia Acquisition, v.1.7.10 Pinnacle Technology RRID:SCR_016183 https://www.pinnaclet.com
Other
Axon Axopatch 200B Microelectrode Amplifier Molecular Devices Cat#: 200B https://www.moleculardevices.com/
sites/default/files/en/assets/data-sheets/dd/cns/
axon-axopatch-200b-microelectrode-amplifier.pdf
ChemiDoc XRS Bio-Rad Cat#: 1708265 http://www.bio-rad.com/en-uk/
product/chemidoc-xrs-system?ID=NINJHRKG4
Crytostat ThermoFisher Scientific Cat#: HM525 No longer available
Leica VT1000 S Vibrating blade microtome Leica Cat#: VT1000 S https://www.leicabiosystems.
com/histology-equipment/sliding-and-vibrating-
blade-microtomes/vibrating-blade-microtome/
products/leica-vt1000-s/
Nikon A1 confocal scanning laser microscope Nikon Cat#: A1HD25 https://www.microscope.
healthcare.nikon.com/products/confocal-
microscopes/a1hd25-a1rhd25
Nikon Eclipse E800 Brightfield Microscope Nikon No longer available
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Stephen
J. Moss (Stephen.moss@tufts.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal Studies
Animals were cared for in accordance with the NIH Guide for the Care and Use of Laboratory Animals, and all protocols were
approved by the Institutional Animal Care and Use Committee (IACUC) of Tufts University School of Medicine. Gabra1-2 animals
were generated by Genoway (Lyon, France) and maintained in the vivarium at Tufts University’s Boston campus on a 12-hour
light/dark cycle with constant temperature and humidity. All animals except those that underwent EEG/EMG surgery were group-
housed and had access to food and water ad libitum, with once weekly cage changes. Germline transmission of the transgene
was detected using PCR with primers spanning the intronic region containing the remaining LoxP site. After founder Gabra1-2
mice were received from Genoway, mice were backcrossed onto the C57Bl6J line for at least 10 generations prior to experiments.
For all experiments, nontransgenic (wild-type,WT) littermates were used as controls. a2 surface expression experiments involved the
generation of a Gabra1-2/Myc-pHlourin-a2 (pHa2) double homozygote line. Gabra1-2 homozygotes and preexisting pHa2 homozy-
gotes were bred for several generations until double homozygotes were born. In pHa2 animals, a pHlourin and Myc tag is incorpo-
rated into the N-terminal of the mature a2 subunit protein (Nakamura et al., 2016), allowing for better detection of low levels of a2
expression. In experiments involving the double homozygotes, WT/pHa2 littermates were used as controls. Rescue and survival
experiments involved the generation ofGabra1-2/Gabra2-1 heterozygotes, which was achieved by breedingGabra1-2 homozygotes
and preexisting Gabra2-1 homozygotes (Hines et al., 2018) together. All experiments save cell culture immunocytochemistry (ICC)
and co-immunoprecipitation employed only male mice, aged 8-12 weeks. Co-immunoprecipitation experiments used age- and
sex-matched 8-12-week old male and female mice.
Cell Culture
Primary cultures of hippocampal neurons for ICC were prepared from monogenotype WT and homozygous Gabra1-2 litters.
Hippocampi from anaesthetized WT and Gabra1-2 P0 male and female neonates were dissected in ice-cold Hank’s buffered salt
solution (HBSS, ThermoFisher, #14185052) with 10 mM HEPES and subsequently pooled and incubated with 0.1% (v/v) trypsin
(ThermoFisher, #15090046) in HBSS for 20minutes at 37C. Cells were thenwashed one timewith HBSS and triturated in freshmedia
to dissociate neurons. After filtering with a 40 mm nylon mesh strainer (ThermoFisher, #22363547) to remove non-dissociated tissue,
resulting hippocampal neurons were counted on a hemocytometer and plated on poly-L-lysine (1 mg/mL, Sigma, #P1274)- and
laminin (1mg/mL, Sigma, #L2020)-coated glass coverslips in 35 mm dishes with 3 mL of Neurobasal-A culture medium
(ThermoFisher, #10888022) containing 2% B27 (v/v; ThermoFisher, #17504044), 1% penicillin/streptomycin (v/v; ThermoFisher,
#15140122), 0.6% D-glucose (w/v; Sigma, #G8270), and 1% GlutaMAX (v/v; ThermoFisher, #35050061) at a density of 5 3 105
cells/dish. Cells were grown at 37C, 5% CO2 and 95% humidity, and allowed to mature for 21 days (Day in vitro 21, DIV21).
METHOD DETAILS
Cresyl violet staining
8-12-week-old male WT and Gabra1-2 mice were transcardially perfused with 30 mL of phosphate buffered saline (PBS, pH 7.4),
followed by 60mL of 4% (v/v) paraformaldehyde in 0.15M sodium phosphate buffer (PFA). Brains were post-fixed in PFA for 3 hours,
then washed in PBS and transferred to 30% sucrose solution for cryoprotection. Brains were embedded in optimal cutting temper-
ature compound (ThermoFisher, #23730571) and frozen at 80C. Brains were subsequently sliced on a cryostat (ThermoFisher,
#HM 525) into 40 mm sections and mounted onto gelatin-coated glass slides (Southern Biotech, #SLD01-CS). Mounted sections
were sequentially washed for 1 minute in (all v/v) 75% ethanol, 95% ethanol, 100% ethanol, distilled water, and then incubated in
filtered cresyl violet solution for 10 minutes (0.3% glacial acetic acid v/v, 0.5% cresyl violet acetate w/v). Staining was followed by
1-minute sequential washes in distilled water, 75% ethanol, 95% ethanol, 100% ethanol, and xylene. Images were acquired using
a Nikon E800 microscope (Nikon) with a 4x objective. 3 animals per genotype were imaged.
Western blotting
8-12-week-old male WT and Gabra1-2 mice were anaesthetized with isofluorane and their brains were rapidly removed. Whole
hippocampi were dissected out and mechanically homogenized with a 26G needle in ice-cold lysis buffer containing 5 mM EDTA,
5 mM EGTA, 1 mM sodium orthovanadate, 100 mM NaCl, 10 mM NaH2PO4, 25 mM NaF, 2% Triton-X (v/v), and protease (mini
cOmplete, Roche, #11836153001) and phosphatase inhibitor cocktails (PhosStop, Roche, #4906845001). Tissue was allowed to
lyse on a rotator for 30minutes at 4C. Samples were then centrifuged at 13,000rmp for 15minutes at 4C to pellet insoluble material.
Following lysis, protein concentration of the supernatant was assessed with a bicinchoninic acid (BCA) assay (Pierce, #23225)
and samples (50 mg) were boiled for 10 minutes at 70C in NuPAGE LDS Sample Buffer (Invitrogen, #NP0007) containing 1% (v/v)Cell Reports 28, 670–681.e1–e8, July 16, 2019 e4
b-mercaptoethanol. Samples were loaded onto NuPAGE 4%–12% Bis-Tris gels (Invitrogen, #NP0335) and run with MES SDS
running buffer (Invitrogen, #NP0002) at 100 V for 2 hours. After separation by SDS-PAGE, proteins were transferred to nitrocellulose
membranes using a wet transfer system (transfer buffer: 25 mM Tris, 192 mM glycine, 20% methanol) for 1 hour at 100 V. After
transfer, membranes were blocked in 5%milk in tris-buffered saline with 1% (v/v) Tween-20 (TBS-T) for 1 hour at room temperature.
Membranes were then incubatedwith their respective primary antibodies diluted into blocking solution overnight at 4C (see Table S1
for antibody sources and concentrations). After 3 washes in TBS-T, membranes were probed with HRP-conjugated secondary
antibodies diluted into blocking solution (1:5000, Jackson ImmunoResearch Laboratories, see Table S1 for complete list) for
1 hour at room temperature. Blots were washed 3 times in TBS-T and developed with a chemiluminescence system as per manu-
facturer’s instructions (Pierce ECL, ThermoFisher, #32106). Blots were imaged (ChemiDoc XRS, Bio-Rad; paired with Image Lab 5.0,
Bio-rad) and band densitometry was measured with ImageJ v.2.0.0 (NIH). For quantification, specific protein levels were determined
by normalizing to GAPDH loading control densitometry results. Gabra1-2 protein levels were normalized to WT control (100%).
5 independent experiments were performed for all western blotting experiments. Unpaired t tests with Welch’s correction were
performed on GraphPad Prism v.7.01 to compare mean values between WT and Gabra1-2, with values below *p < 0.05 considered
significant. Graphs were plotted as mean ± standard error of the mean (SEM).
Biotinylation of cell surface proteins
8-12-week-old male mice of all genotypes (WT and Gabra1-2 homozygous for a1; pHa2 and pHa2/Gabra1-2 homozygous for a2)
were anaesthetized with isofluorane and their brains were rapidly removed. 350 mm-thick coronal hippocampal slices were pre-
pared and sectioned on a vibratome (Leica VT1000S) in ice-cold cutting solution containing 87 mM NaCl, 2.5 mM KCl, 0.5 mM
CaCl2, 25 mM, NaHCO3, 1.25 mM NaH2PO4, 7 mM MgCl2, 50 mM sucrose, and 25 mM glucose. After sectioning, slices were
allowed a 1-hour recovery period in 32C artificial cerebrospinal fluid (aCSF) containing 126 mM NaCl, 26 mM NaHCO3,
2.5 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 1mM glutamine, 1.25 mM NaH2PO4, 1.5 mM sodium pyruvate, and 10 mM glucose.
Following recovery, slices were incubated for 45 minutes in ice-cold, 1 mg/mL EZ-Link Sulfo-NHS-SS-biotin (ThermoFisher,
#21328T) in aCSF. All solutions described above were oxygenated with 95% (v/v) O2/5% (v/v) CO2. After 3 rinses in ice-cold
100 mM glycine in aSCF to halt the biotin reaction and 2 washes in ice-cold plain aCSF, samples were mechanically homogenized
with a 26G needle and lysed in the previously described lysis buffer. Lysis was carried out as described above. After adjusting for
protein concentration measured by BCA assay, hippocampal lysates (500 mg) were incubated with 50 mL of Strepavidin Agarose
beads (ThermoFisher, #20347) on a rotator at 4C overnight, with a portion (50 mg) reserved for total protein analysis. The super-
natant was removed, and beads were washed in lysis buffer 3 times. All samples were mixed with NuPAGE LDS Sample Buffer
(Invitrogen, #NP0007)/1% (v/v) b-mercaptoethanol. Samples were then boiled for 10 minutes at 70C. Bound proteins and total
protein samples were subjected to SDS and immunoblotting (see Table S1 for antibody sources and concentrations), developed,
and imaged as described above. Band densitometry was measured with ImageJ v.2.0.0 (NIH) and protein levels were determined
by normalizing to GAPDH (total protein) and/or pan-cadherin (surface protein) loading controls. The ratio of surface protein:total
protein was calculated, and Gabra1-2 values were normalized to WT or pHa2 control (100%). 5 independent experiments were
performed for all biotinylation experiments. Unpaired t tests with Welch’s correction were performed on GraphPad Prism
v.7.10 to compare mean values between WT and Gabra1-2 or pHa2 and Gabra1-2/pHa2, with data below p < 0.05 considered
significant. Graphs were plotted as mean ± SEM.
Co-Immunoprecipiation (coIP)
Forebrains (cortex and hippocampus) were rapidly removed from isofluorane-anaesthetized 8-12-week-oldmale and femaleWT and
Gabra1-2mice and collected in an ice-cold cryoprotectant buffer (225mMmannitol, 75mMsucrose, 30mMTris-HCl, pH 7.4). Tissue
was mechanically homogenized using 14 strokes of a dounce homogenizer in homogenization buffer (225 mM mannitol, 75 mM
sucrose, 0.5% (w/v) BSA, 0.5 mM EGTA, 30 mM Tris-HCl, pH 7.4) and subjected to the following sequential centrifugation, all at
4C: two 5-minute spins at 800 x g to remove unbroken cells; two 10-minute spins at 10,000 x g to remove mitochondria; and
two 20-minute spins at 25,000 x g to isolate plasma membrane (PM) fractions. PM fractions were re-suspended and lysed in a lysis
buffer containing 150 mM NaCl, 10 mM Tris, 0.5% Triton-X, and protease and phosphatase inhibitor cocktails, as above. These PM
lysates (5000 mg protein) were incubated with 150 mL Protein A Dynabeads (ThermoFisher, #10001D) cross-linked to 15 mg of
N-terminal a1 antibody (Abcam, #ab33299) overnight at 4C. Supernatant was removed, and beads were washed 3 times in PBS
with 0.05% (v/v) Tween. All samples were eluted in SDS-PAGE sample buffer. Immunoprecipitation samples were first boiled at
55C for 10 minutes to remove protein complexes from the beads, and then both total lysate and immunoprecipitation samples
were boiled at 95C for 5minutes. Samples were run through SDS-PAGE andwestern blotting for the appropriate proteins and devel-
oped and imaged as detailed above (see Table S1 for antibody sources and concentrations). For quantification using ImageJ v.2.0.0
(NIH), relative immunoprecipitation levels were determined by first normalizing to a1 densitometry results to account for differences in
the amount of a1 present in WT versus Gabra1-2 samples. Gabra1-2 protein levels were then normalized to WT control (100%).
4 independent experiments were performed for the coIP experiments. Unpaired t tests with Welch’s correction were performed
on GraphPad Prism v.7.10 to compare mean values between WT and Gabra1-2, with data below p < 0.05 considered significant.
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Immunocytochemistry (ICC)
DIV21 primary hippocampal WT and Gabra1-2 cells were washed once in PBS and fixed for 20 minutes in a solution of 4% (w/v)
sucrose and 4% (v/v) paraformaldehyde in PBS. After 3 PBS washes to remove fixative, cells were blocked in a solution containing
5% (w/v) bovine serum albumin (BSA) for 1 hour at room temperature. Cells were then incubated with the appropriate primary anti-
bodies (see Table S1 for details) diluted into a modified blocking solution containing 2.5% (w/v) BSA, 2% (v/v) normal goat serum
(NGS), and 0.1% (v/v) Triton-X for 2 hours at room temperature. After 10 washes in PBS to remove unbound antibody, cells were
incubated with Alexa conjugated secondary antibodies (1:5000, ThermoFisher, see Table S1 for details) in modified blocking solution
for 1 hour at room temperature. Cells were washed with PBS 10 times and mounted on glass slides (Electron Microscopy Sciences,
#71864) using ProLong Gold Antifade mounting media (ThermoFisher, #P36930).
Images were acquired with a Nikon A1 confocal scanning laser microscope coupled with NIS Elements software v.4.20 (Nikon).
Images were taken at a 512 3 512 resolution (17 nm/pixel) with a 60x (oil, numerical aperture: 1.00) objective, with the imager blind
to genotype. Settings were optimized to ensure low background and sufficient signal/noise ratio, and within experiments settings
were unchanged between genotypes. Images were saved as single-channel and overlay 8-bit TIF-files. Immunostaining density
(the number of puncta per 10 mmof neurite/soma) and area were quantified usingMetaMorph software (Molecular Devices). For defi-
nition of image thresholds, the brightness of single-channel images was adjusted with the ‘‘inclusive thresholding’’ function. Within
each experiment, threshold adjustments were unchanged between genotypes. Puncta number and size was assessed using the
MetaMorph-based ‘‘Integrated Morphometry Analysis’’ tool, which calculated the number, area, and average intensity of single
objects > 0.05 mm. Co-localization analysis (calculation of the Pearson’s correlation coefficient) between single-channel images
was achieved with the Coloc2 macro on ImageJ v.2.0.0/Fiji (https://imagej.net/ImageJ). A region of interest (ROI) containing both
the soma and neurites of each neuron was defined on 1 channel using the polygon drawing tool and transferred to the other channel.
Background was subtracted using a Rolling-Ball Background Subtraction of 50. All analysis was performed blinded to genotype.
3 independent experiments were performed for each antibody combination and within each experiment 10 neurons were imaged
and analyzed per genotype. Results were analyzed onGraphPad Prism v.7.10with unpaired t tests to comparemean values between
WT and Gabra1-2, with data below p < 0.05 considered significant. Graphs were plotted as the mean ± SEM.
Electrophysiology
Brain slices were prepared from 4-6-week-old WT and Gabra1-2 male, isofluorane-anaethetized mice. 300 mm sections were cut in
ice-cold, oxygentated saline (92mMNMDG, 2.5mMKCl, 1.25mMNaH2PO4, 30mMNaHCO3, 20mMHEPES, 25mMglucose, 2mM
thiourea, 5mMNa-ascorbate, 3mMNa-pyruvate, 0.5mMCaCl2, 10mMMgSO4) using a vibratome (VT1000S, Leica), then incubated
at 32C for 10 minutes in holding aSCF (92 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 30 mM NaHCO3, 20 mM HEPES, 25 mM
glucose, 2 mM thiourea, 5 mM Na-ascorbate, 3 mM Na-pyruvate, 2 mM CaCl2, 2 mM MgSO4). Brain slices were then transferred
to the recording chamber and were continually perfused with normal aCSF (126 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 2 mM
MgCl2, 26 mM NaHCO3, 1.25 mM NaH2PO4, 10 mM glucose, 1.5 mM Na-pyruvate, 1 mM glutamine, 3 mM kynurenic acid,
0.005 M GABA) at 32C. All solutions were bubbled with 95% (v/v) O2/5% (v/v) CO2. Patch pipettes (5-7 MU) were pulled from
borosilicate glass (World Precision Instruments) and filled with intracellular solution (140 mM CsCl, 1 mM MgCl2, 0.1 mM EGTA,
10 mMHEPES, 2 mMMg-ATP, 4 mMNaCl, 0.3 mMNa-GTP, pH to 7.2 with CsOH). To examine mini inhibitory postsynaptic currents
(mIPSCs), tetrodotoxin (TTX; 0.5 mM) was added to the aCSF. A 5-minute stabilization period was allowed after obtaining the whole-
cell recording conformation (holding potential of 60 mV) in the hippocampal CA1. Subsequently, currents were recorded using an
Axopatch 200B amplifier (Molecular Devices), low-pass filtered at 2 kHz, digitized at 20 kHz (Digidata 1440A;Molecular Devices), and
stored for offline analysis. Series resistance andwhole-cell capacitancewere continually monitored and compensated for throughout
the course of the experiment. Recordings were eliminated from data analysis if series resistance increased by > 20%. mIPSCs were
analyzed using mini-analysis software v.5.6.4 (Synaptosoft). Minimum threshold detection was set to 3x the value of baseline noise
signal. To assess mIPSC kinetics, the recording trace was visually inspected and only events with a stable baseline, sharp rising
phase, and single peak were used to negate artifacts from event summation. Only recordings with a minimum of 200 events fitting
these criteria were analyzed. mIPSC amplitude and frequency from each experimental condition were pooled and expressed as
mean ± SEM. To measure mIPSC decay, we averaged 100 consecutive events, fit the decay to a double exponential, and
took the weight decay constant (s). Statistical analysis for mean mIPSC kinetics was performed using a Mann-Whitney test, where
p < 0.05 is considered significant. To display the distribution of mIPSC amplitudes, data was fitted with a Gaussian function:
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Where A is the amplitude, m is the Gaussian mean amplitude current, s the Gaussian standard deviation, and C is the constant for
each component i.
For tonic current measurements in the CA1, once the response reached a plateau level an all-points histogram was plotted for a
10 s period before and during 100 mM picrotoxin application. Recordings with unstable baselines were discarded. Fitting the
histogram with a Gaussian distribution gave the mean baseline current amplitude. The difference between the amplitudes before
and during picrotoxin application was considered to be the tonic current. The negative section of the all-points histogram whichCell Reports 28, 670–681.e1–e8, July 16, 2019 e6
corresponds to the inward IPSCs was not fitted with a Gaussian distribution (Kretschmannova et al., 2013; Nusser and Mody, 2002).
Tonic current was analyzed with a Student’s t test, where p < 0.05 is considered significant.
Motor behavior
Genotype-blinded behavioral testing was performed on group-housed 8-12-week-old male WT and Gabra1-2 mice. All behavioral
testing occurred during the light phase between 9am and 4pm, following at least 1 hour of habituation to the temperature controlled
(70-74C) behavioral testing facility. Littermates were used for all experiments. Protocols for all testing were based on standard
protocols. Equipment was cleaned between each mouse using 70% ethanol followed by Clidox (chlorine dioxide based sterilant).
For assessment of motor behavior, the rotarod test and open field test (OFT) were employed. During the rotatrod test, mice were
placed on the rotarod apparatus (Med Associates; rubber-coated cylinder 4 cm in diameter, fixed 30 cm above ground) and trained in
the task in three 3-minute trials at a speed of 16 rotations per minute (rpm), with a 15-minute inter-trial interval. After completion of
training, the animals were returned to their homecage and allowed to recover for an additional 15 minutes before testing began.
Rotarod testing was conducted on an accelerated speed setting, with rotarod speeds increasing from 4 to 40 rpm over the course
of 5minutes. Animals were subject to three 5-minute-maximum tests, again with an inter-trial interval of 15minutes. The latency to fall
off the rotarod beam or to lose control (defined as 3 rotations around the cylinder without active movement) was measured for each
test, and the average latency was calculated for each animal.
In the OFT, mice were individually placed in the center of a 60 cm x 60 cm white-walled box and allowed to freely explore for
10 minutes. The OFT box was positioned inside a photobeam frame with 16 3 16 equally spaced photo emitters and detectors
(Kinder Scientific). The frames connected to MotorMonitor software (Kinder Scientific), which measured the total distance traveled
for each mouse. All behavioral tests used 10 mice per genotype in at least 3 independent cohorts. All results were analyzed on
GraphPad Prism v.7.10 with one-way analysis of variance (ANOVA), with posthoc testing comparing the means between WT and
Gabra1-2 hetero- and homozygotes. Data below p < 0.05 was considered significant. Graphs were plotted as mean ± SEM.
Electroencephalography (EEG)
Surgery and recording
8-12-week-old male WT and Gabra1-2 littermates were used for EEG studies. Prefabricated EEG and electromyography (EMG)
headmounts (2-channel, Pinnacle Technology, #8201) were implanted under isofluorane anesthesia (3%–5% for induction,
1%–2% for maintenance). Mice were given 0.1 mg/kg buprenorphine i.p. as an additional analgesic. All surgical instruments were
heat-sterilized. The fur covering the scalp was shaved off and the scalp itself was sterilized with 3 applications of b-iodine, with a
wash of 70% ethanol between each application. Scissors were used to make an incision down the vertical midline of the scalp to
expose the skull. The skull was then washed with a sterile Q-tip soaked in 70% ethanol. The EEG/EMG headmount was aligned
with lambda and secured to the skull with two 0.10 inch and two 0.12-inch ground screws (Pinnacle Technology, #8209 and
#8212, respectively). Two of the screws served as EEG leads in the frontal cortex, 1 as a reference ground, and 1 as an animal ground.
Dental cement was used to close the scalp and secure the headmount. Mice were singly-housed post-surgery. After a minimum of
7 days of recovery, EEG and EMG recordings were collected with Sirenia Acquisition software v.1.7.10 (Pinnacle Technology).
Recordings were performed in awake, behaving WT and Gabra1-2 mice. Animals were given 1 hour of habituation to the recording
chamber and the preamplifier. For baseline EEG activity, EEG/EMG recordings were then collected for 2 hours. For epileptic EEG
activity, EEG/EMG recordings were collected for 1 hour pre- and 2 hours post-injection of the chemoconvulsant kainic acid (KA;
20 mg/kg i.p.; Sigma, #K0250). All recordings were processed and analyzed blind with pClamp v.10.3 (Molecular Devices) and
Labchart v.7.3.8 (AD Instruments) software.
Baseline analysis
Power analysis was performed using LabChart software v.7.3.8. Fast-Fourier transform (FFT) was used to transform 10 minutes of
awake baseline activity from the time domain to the frequency domain to generate a power spectral density plot (FFT size 4K, 93.7%
overlap, Hanns window function). Activity was then binned into the following frequency bands: delta (1-4 Hz), theta (4-8 Hz), alpha
(8-13 Hz), beta (13-30 Hz), low gamma (30-50 Hz), and high gamma (50-100 Hz). 9 animals per genotype were used in at least 3
separate cohorts. The power of each frequency band was expressed as a percentage of the total EEG power and plotted as
the mean ± SEM. Unpaired t tests were performed with GraphPad Prism v.7.10 to compare genotype means, and data below
p < 0.05 was considered significant.
Seizure analysis
The latency to the first seizure event and the latency to the onset of status epilepticus (SE) was measured with pClamp software
v.10.3. Epileptiform activity was defined as having an amplitude of at least 2.5x the standard deviation of baseline activity and lasting
for at least 30 s. Latency to the first seizure was defined as the time from KA injection to the start of the first detected electrographic
seizure. SE was defined as continuous epileptiform activity lasting at least 5 minutes, with no more than 30 s between epileptiform
events. Latency to SEwas defined as the time fromKA injection to the start of the first period of such activity. As above, FFTwas used
to transform the first hour after KA injection from the time domain to the frequency domain to generate a power spectral density plot
(FFT size 4K, 93.7% overlap, Hanns window function). Activity was then binned into the same frequency bands as above. Mortality
during the post-KA period was also assessed. 9 animals per genotype were used in at least 3 separate cohorts. Gabra1-2 data
(latency to first seizure and latency to SE) was normalized to WT littermate controls to account for variability due to differencese7 Cell Reports 28, 670–681.e1–e8, July 16, 2019
in KA potency between cohorts. Results were analyzed with GraphPad Prism v.7.10 using either unpaired t tests or unpaired t tests
with Welch’s correction, where appropriate, to compare mean values between WT and Gabra1-2. Graphs were plotted as the
mean ± SEM. Mortality data was plotted as a survival curve and analyzed with a log-rank (Mantel-Cox) test. Data below p < 0.05
was considered significant.
Survival assessments
Assessment of postnatal survival comparingGabra2-1 heterozygotes andGabra1-2/Gabra2-1 heterozygotes was performed. Litters
were observed by the investigator once per day until weaning at postnatal day 21 (PND21) to check for pup death. After weaning,
offspring were observed once per day to check for mortality until PND40. At least 20 pups per condition were assessed. Results
were plotted with GraphPad Prism v.7.10 as the percent of animals alive from PND0-PND40.
QUANTIFICATION AND STATISTICAL ANALYSIS
All programs used for quantification and statistical analysis are outlined in the Method Details section. Statistical analyses are
described in the corresponding figure legends and also in the Method Details section.Cell Reports 28, 670–681.e1–e8, July 16, 2019 e8
